DD212735A5 - Verfahren zur herstellung neuer peptide - Google Patents

Verfahren zur herstellung neuer peptide Download PDF

Info

Publication number: DD212735A5
Authority: DD; German Democratic Republic
Prior art keywords: boc; resin; tyr; vasopressin; pro
Prior art date: 1981-03-24

Application number

DD82255304A

Other languages

German (de)

English (en)

Inventor

Maurice Manning

Wilbur H Sawyer

Original Assignee

Ohio Med College

Univ Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-03-24

Filing date

1982-03-24

Publication date

1984-08-22

1981-03-24 Priority claimed from US06/247,008 external-priority patent/US4367225A/en

1982-03-24 Application filed by Ohio Med College, Univ Columbia filed Critical Ohio Med College

1984-08-22 Publication of DD212735A5 publication Critical patent/DD212735A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 16
230000008569 process Effects 0.000 title claims abstract description 6
238000002360 preparation method Methods 0.000 title claims description 7
108090000765 processed proteins & peptides Proteins 0.000 title abstract description 15
102000004196 processed proteins & peptides Human genes 0.000 title abstract description 9
150000001875 compounds Chemical class 0.000 claims abstract description 26
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 13
229940124280 l-arginine Drugs 0.000 claims abstract description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
239000011347 resin Substances 0.000 claims description 25
229920005989 resin Polymers 0.000 claims description 25
-1 S-benzylmercapto Chemical class 0.000 claims description 10
229940024606 amino acid Drugs 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 10
230000008878 coupling Effects 0.000 claims description 9
238000010168 coupling process Methods 0.000 claims description 9
238000005859 coupling reaction Methods 0.000 claims description 9
CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 claims description 6
150000001408 amides Chemical class 0.000 claims description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 claims description 3
230000003472 neutralizing effect Effects 0.000 claims description 3
238000007243 oxidative cyclization reaction Methods 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
241000607479 Yersinia pestis Species 0.000 claims 1
238000001308 synthesis method Methods 0.000 claims 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract description 31
230000002686 anti-diuretic effect Effects 0.000 abstract description 21
101800001144 Arg-vasopressin Proteins 0.000 abstract description 19
239000005557 antagonist Substances 0.000 abstract description 18
230000000694 effects Effects 0.000 abstract description 4
102400000059 Arg-vasopressin Human genes 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 33
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 25
229960003726 vasopressin Drugs 0.000 description 21
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 17
239000004474 valine Substances 0.000 description 17
239000000243 solution Substances 0.000 description 16
108010004977 Vasopressins Proteins 0.000 description 15
102000002852 Vasopressins Human genes 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
235000019260 propionic acid Nutrition 0.000 description 13
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 13
JITASQOSGITBPR-FMCGBTBPSA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylidene Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(N)=O)=O)C(C)C)C1=CC=CC=C1 JITASQOSGITBPR-FMCGBTBPSA-N 0.000 description 12
108700003795 Val(4)- argipressin Proteins 0.000 description 12
230000004044 response Effects 0.000 description 11
239000003160 antidiuretic agent Substances 0.000 description 10
229940124538 antidiuretic agent Drugs 0.000 description 10
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229940124572 antihypotensive agent Drugs 0.000 description 9
239000005526 vasoconstrictor agent Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
238000001727 in vivo Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 6
239000000556 agonist Substances 0.000 description 6
229960001723 oxytocin Drugs 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
101800000989 Oxytocin Proteins 0.000 description 5
102400000050 Oxytocin Human genes 0.000 description 5
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
230000001396 anti-anti-diuretic effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
KEBRFHAVFOSSOX-WSFLLCRESA-N (2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)C(C)C)C1=CC=CC=C1 KEBRFHAVFOSSOX-WSFLLCRESA-N 0.000 description 3
108700042888 1-deamino-4-Val-8-Arg- vasopressin Proteins 0.000 description 3
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
JLTCWSBVQSZVLT-UHFFFAOYSA-N n-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxa Chemical compound NCCCCC(C(=O)NCC(N)=O)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 JLTCWSBVQSZVLT-UHFFFAOYSA-N 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000010532 solid phase synthesis reaction Methods 0.000 description 3
PKYIYKFMOOJYFL-NLGBYHCPSA-N (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(10r,13s,16s,19s,22s)-13-(2-amino-2-oxoethyl)-19-benzyl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-16-propan-2-yl-7,8-dithia-11,14,17,20,23-pentazaspiro[ Chemical compound C1=CC(OC)=CC=C1C[C@H]1C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)CSSC2(CCCCC2)CC(=O)N1 PKYIYKFMOOJYFL-NLGBYHCPSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
229960003121 arginine Drugs 0.000 description 2
238000009835 boiling Methods 0.000 description 2
GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
QAXZWHGWYSJAEI-UHFFFAOYSA-N n,n-dimethylformamide;ethanol Chemical compound CCO.CN(C)C=O QAXZWHGWYSJAEI-UHFFFAOYSA-N 0.000 description 2
HNOGCDKPALYUIG-UHFFFAOYSA-N n-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-methoxyphenyl)methyl]-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-car Chemical compound C1=CC(OC)=CC=C1CC1C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)CSSC(C)(C)CC(=O)N1 HNOGCDKPALYUIG-UHFFFAOYSA-N 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241001432959 Chernes Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
229930195709 D-tyrosine Natural products 0.000 description 1
150000008572 D-tyrosines Chemical class 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016807 Fluid retention Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
241000750002 Nestor Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 1
MTEUMURLJRZUKD-UHFFFAOYSA-N acetic acid;butan-1-ol;pyridine;hydrate Chemical compound O.CC(O)=O.CCCCO.C1=CC=NC=C1 MTEUMURLJRZUKD-UHFFFAOYSA-N 0.000 description 1
QEEUGKMTENMRQO-UHFFFAOYSA-N acetic acid;chloroform;cyclohexane Chemical compound CC(O)=O.ClC(Cl)Cl.C1CCCCC1 QEEUGKMTENMRQO-UHFFFAOYSA-N 0.000 description 1
WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
JMJRNNLOJLYQLM-UHFFFAOYSA-N azane;propan-1-ol Chemical compound N.CCCO JMJRNNLOJLYQLM-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
KWZWNVAHEQHCTQ-UHFFFAOYSA-N diacetyloxyboranyl acetate Chemical compound CC(=O)OB(OC(C)=O)OC(C)=O KWZWNVAHEQHCTQ-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002196 ecbolic effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
IKNCGYCHMGNBCP-UHFFFAOYSA-N propan-1-olate Chemical compound CCC[O-] IKNCGYCHMGNBCP-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/15—Oxytocin or vasopressin; related peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DD82255304A 1981-03-24 1982-03-24 Verfahren zur herstellung neuer peptide DD212735A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/247,008 US4367225A (en)	1981-03-24	1981-03-24	Novel antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin
US06/322,071 US4399125A (en)	1981-03-24	1981-11-16	Novel antagonists of the antidiuretic action of arginine vasopressin

Publications (1)

Publication Number	Publication Date
DD212735A5 true DD212735A5 (de)	1984-08-22

Family

ID=26938391

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD82255304A DD212735A5 (de)	1981-03-24	1982-03-24	Verfahren zur herstellung neuer peptide
DD82238409A DD202695A5 (de)	1981-03-24	1982-03-24	Verfahren zur herstellung neuer peptide

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD82238409A DD202695A5 (de)	1981-03-24	1982-03-24	Verfahren zur herstellung neuer peptide

Country Status (21)

Country	Link
US (1)	US4399125A (fr)
EP (1)	EP0061356B1 (fr)
KR (1)	KR880000758B1 (fr)
AU (1)	AU546865B2 (fr)
BG (1)	BG38487A3 (fr)
CA (1)	CA1185235A (fr)
DD (2)	DD212735A5 (fr)
DE (1)	DE3264734D1 (fr)
DK (1)	DK130182A (fr)
ES (2)	ES8604264A1 (fr)
FI (1)	FI77047C (fr)
HU (1)	HU189127B (fr)
IE (1)	IE52624B1 (fr)
IL (1)	IL65211A (fr)
NO (1)	NO162024C (fr)
NZ (1)	NZ199908A (fr)
PH (1)	PH19237A (fr)
PT (1)	PT74615B (fr)
RO (1)	RO84361B (fr)
YU (1)	YU63482A (fr)
ZW (1)	ZW4882A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4491577A (en) *	1981-11-16	1985-01-01	The Medical College Of Ohio	Antagonists of the antidiuretic action of arginine vasopressin
DK153883A (da) *	1982-04-20	1983-10-21	Ceskoslovenska Akademie Ved	Vasopressin-analoge
US4587045A (en) *	1983-02-16	1986-05-06	Smithkline Beckman Corporation	Intermediates for preparing octapeptide vasopressin antagonists
US4469679A (en) *	1983-02-16	1984-09-04	Smithkline Beckman Corporation	Octapeptide vasopressin antagonists
US4483794A (en) *	1983-05-10	1984-11-20	Ceskoslovenska Akademie Ved	Analogs of neurohypophysial hormones
CA1238314A (fr) *	1983-09-22	1988-06-21	James F. Callahan	Procede de preparation d'heptapeptides inhibiteurs de la vasopressine
US4551445A (en) *	1983-10-14	1985-11-05	The Medical College Of Ohio	Derivatives of arginine vasopressin antagonists
US4714696A (en) *	1984-01-26	1987-12-22	Medical College Of Ohio	Novel derivatives of arginine vasopressin antagonists
US4649130A (en) *	1984-01-26	1987-03-10	Medical College Of Ohio	Novel derivatives of arginine vasopressin antagonists
US4481193A (en) *	1984-03-07	1984-11-06	Smithkline Beckman Corporation	Des-proline vasopressin antagonists
CA1249397A (fr) *	1984-03-07	1989-01-24	Fadia E. Ali	Procede de preparation de la des-proline inhibitrice de la vasopressine
US4481194A (en) *	1984-03-07	1984-11-06	Smithkline Beckman Corporation	Des-proline-des-glycine vasopressin antagonists
US4597901A (en) *	1984-12-14	1986-07-01	Smithkline Beckman Corporation	β-indolylalanyl or β-indolylglycinyl vasopressin antagonists
US4719199A (en) *	1984-12-14	1988-01-12	Smithkline Beckman Corporation	Diuretic compositions and methods of producing diuresis
US4684716A (en) *	1984-12-14	1987-08-04	Smithkline Beckman Corporation	Polypeptide intermediates
US4624943A (en) *	1985-03-20	1986-11-25	Smithkline Beckman Corporation	Aromatic basic-tailed vasopressin antagonists
WO1987002676A1 (fr) *	1985-10-25	1987-05-07	Gibson-Stephens Neuropharmaceuticals, Inc.	Antagonistes de l'oxytocine a conformation limitee presentant des activites biologiques prolongees
PT84342B (pt) *	1986-02-25	1989-09-14	Smithkline Beecham Corp	Processo de preparacao de compostos de vasopressina
US4762820A (en) *	1986-03-03	1988-08-09	Trustees Of Boston University	Therapeutic treatment for congestive heart failure
WO1988005661A1 (fr) *	1987-01-30	1988-08-11	Biomed Research Consultants, Limited	Compositions pharmaceutiques a base de vasopressine
US5055448A (en) *	1987-06-25	1991-10-08	Medical College Of Ohio	Linear derivatives of arginine vasopressin antagonists
AT398766B (de) *	1988-05-26	1995-01-25	Gebro Broschek Gmbh	Verfahren zur intramolekularen oxidation von zwei -sh gruppen in einer peptidverbindung zu einer disulfidbrücke
US5070187A (en) *	1989-11-03	1991-12-03	Trustees Of Boston University	Pharmacologically effective antagonists of arginine-vasopressin
US5051400A (en) *	1990-06-28	1991-09-24	Smithkline Beecham Corporation	Method of treating nausea and emesis related to motion sickness with vasopressin antagonists
RU2342949C1 (ru) *	2007-03-26	2009-01-10	Юрий Георгиевич Жуковский	Применение [дезамино-1, изолейцин-3, аргинин-8]вазопрессина в качестве средства для увеличения выведения почкой солей натрия и усиления обратного избирательного всасывания из почечных канальцев в кровь воды-растворителя
CN111253569B (zh) *	2020-02-26	2021-06-01	山东大学	一种聚合物、其制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1193509B (de) *	1960-06-02	1965-05-26	Hoechst Ag	Verfahren zur Herstellung eines neuen Oktapeptids mit vasopressorischer Wirksamkeit
CH426861A (de) *	1963-06-06	1966-12-31	Sandoz Ag	Verfahren zur Herstellung eines bisher unbekannten Polypeptids
CH442342A (de) *	1964-07-17	1967-08-31	Sandoz Ag	Verfahren zur Herstellung eines neuen Polypeptids
CH460039A (de) *	1965-04-15	1968-07-31	Sandoz Ag	Verfahren zur Herstellung eines neuen Polypeptids
CH495957A (de) *	1966-09-15	1970-09-15	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4148787A (en) *	1976-05-24	1979-04-10	Ferring Ab	Antidiuretically effective polypeptide and a process for preparing the same

1981
- 1981-11-16 US US06/322,071 patent/US4399125A/en not_active Expired - Fee Related
1982
- 1982-03-02 IE IE465/82A patent/IE52624B1/en unknown
- 1982-03-03 CA CA000397464A patent/CA1185235A/fr not_active Expired
- 1982-03-04 NZ NZ199908A patent/NZ199908A/xx unknown
- 1982-03-09 IL IL65211A patent/IL65211A/xx unknown
- 1982-03-10 PH PH26975A patent/PH19237A/en unknown
- 1982-03-16 ZW ZW48/82A patent/ZW4882A1/xx unknown
- 1982-03-17 AU AU81617/82A patent/AU546865B2/en not_active Ceased
- 1982-03-18 ES ES510579A patent/ES8604264A1/es not_active Expired
- 1982-03-19 PT PT74615A patent/PT74615B/pt unknown
- 1982-03-23 DK DK130182A patent/DK130182A/da not_active Application Discontinuation
- 1982-03-23 HU HU82880A patent/HU189127B/hu unknown
- 1982-03-23 BG BG055925A patent/BG38487A3/xx unknown
- 1982-03-23 FI FI821019A patent/FI77047C/fi not_active IP Right Cessation
- 1982-03-23 NO NO820967A patent/NO162024C/no unknown
- 1982-03-23 KR KR8201234A patent/KR880000758B1/ko not_active Expired
- 1982-03-23 RO RO107007A patent/RO84361B/ro unknown
- 1982-03-24 DD DD82255304A patent/DD212735A5/de not_active IP Right Cessation
- 1982-03-24 DE DE8282301555T patent/DE3264734D1/de not_active Expired
- 1982-03-24 EP EP82301555A patent/EP0061356B1/fr not_active Expired
- 1982-03-24 YU YU00634/82A patent/YU63482A/xx unknown
- 1982-03-24 DD DD82238409A patent/DD202695A5/de not_active IP Right Cessation
1985
- 1985-08-14 ES ES546137A patent/ES8703489A1/es not_active Expired

Also Published As

Publication number	Publication date
EP0061356A2 (fr)	1982-09-29
DK130182A (da)	1982-09-25
IL65211A (en)	1986-02-28
FI77047B (fi)	1988-09-30
IL65211A0 (en)	1982-05-31
PT74615B (en)	1983-10-20
ES510579A0 (es)	1986-01-16
BG38487A3 (en)	1985-12-16
KR880000758B1 (ko)	1988-05-06
IE52624B1 (en)	1988-01-06
NO162024B (no)	1989-07-17
YU63482A (en)	1985-10-31
FI821019L (fi)	1982-09-25
KR830008683A (ko)	1983-12-14
HU189127B (en)	1986-06-30
AU8161782A (en)	1982-09-30
EP0061356A3 (en)	1982-12-29
NO820967L (no)	1982-09-27
NZ199908A (en)	1985-09-13
EP0061356B1 (fr)	1985-07-17
NO162024C (no)	1989-10-25
FI821019A0 (fi)	1982-03-23
FI77047C (fi)	1989-01-10
DD202695A5 (de)	1983-09-28
DE3264734D1 (en)	1985-08-22
ES8703489A1 (es)	1987-03-01
US4399125A (en)	1983-08-16
RO84361A (fr)	1984-05-23
CA1185235A (fr)	1985-04-09
ES546137A0 (es)	1987-03-01
RO84361B (ro)	1984-07-30
ZW4882A1 (en)	1983-02-23
IE820465L (en)	1982-09-24
PT74615A (en)	1982-04-01
PH19237A (en)	1986-02-14
ES8604264A1 (es)	1986-01-16
AU546865B2 (en)	1985-09-26

Legal Events

Date	Code	Title	Description
1996-05-23	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD212735A5 (de)	1984-08-22	Verfahren zur herstellung neuer peptide
US4367225A (en)	1983-01-04	Novel antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin
CH629475A5 (de)	1982-04-30	Verfahren zur herstellung von polypeptiden.
CH634039A5 (de)	1983-01-14	Somatostatinanalogon, sowie verfahren zu seiner herstellung.
DE1543796A1 (de)	1970-01-02	Verfahren zur Herstellung biologisch aktiver Peptide
US4491577A (en)	1985-01-01	Antagonists of the antidiuretic action of arginine vasopressin
DE2705514B2 (de)	1979-06-07	Nonapeptide und diese enthaltende Arzneimittel
CH649562A5 (de)	1985-05-31	Derivate des methionin-enzephalins.
DE2629195C3 (de)	1983-11-17	Tripeptide und deren Verwendung zur Bestimmung von Thrombin
DE2734628A1 (de)	1978-02-09	Fuer die erhoehung der futterausnutzung geeignete cyclische hexapeptide
CH655929A5 (de)	1986-05-30	Biologisch wirksame 2,5-piperazindionderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3314357A1 (de)	1983-10-27	Vasopressin-analoga, ihre herstellung und pharmazeutische mittel
EP0034260B1 (fr)	1983-07-20	Peptides, procédé pour leur préparation et médicaments ou agents de diagnostic les contenant
DE2739440A1 (de)	1978-03-02	Pentapeptide und sie enthaltende arzneimittel
DE69419910T2 (de)	1999-12-09	Oxytocinantagonist
DE2727847A1 (de)	1977-12-29	Polypeptide, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
EP0028716B1 (fr)	1986-11-12	Peptides augmentant l'effet de motilité et leur utilisation
JPS60155197A (ja)	1985-08-15	アルギニン　バソプレツシンきつ抗薬の新規誘導体
DE3236484A1 (de)	1983-04-21	Tripeptide, verfahren zur herstellung derselben und diese enthaltende arzneimittel
JPS61172898A (ja)	1986-08-04	アルギニンバソプレツシン拮抗薬の新規誘導体類
DE2648829A1 (de)	1977-06-16	Nonapeptide, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE2711149B2 (fr)	1980-04-24
WO1992011287A1 (fr)	1992-07-09	Derives de vasopressine et de vasotocine
EP0424670B1 (fr)	1995-02-22	Hexapeptides à activité ZNS exerçant une action antiamnestique
CH634040A5 (en)	1983-01-14	Somatostatin analogues and process for their preparation